BMS-986158
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BMS-986158, covering 2022-06-16 to 2025-09-10. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) [Phase 1, Phase 2]